Potential for the Use of the Solitaire Stent for Recanalization of Middle Cerebral Artery Occlusion without a Susceptibility Vessel Sign

REFERENCES

1. 1.↵
   1. Henkes H,
   2. Flesser A,
   3. Brew S,
   4. et al

   . A novel microcatheter-delivered, highly-flexible and fully-retrievable stent, specifically designed for intracranial use. Interv Neuroradiol 2003;9:391–93

   PubMed
2. 2.↵
   1. Lubicz B,
   2. Collignon L,
   3. Raphaeli G,
   4. et al

   . Solitaire stent for endovascular treatment of intracranial aneurysms: immediate and mid-term results in 15 patients with 17 aneurysms. J Neuroradiol 2010;37:83–88

   CrossRefPubMed
3. 3.↵
   1. Klisch J,
   2. Eger C,
   3. Sychra V,
   4. et al

   . Stent-assisted coil embolization of posterior circulation aneurysms using Solitaire ab: preliminary experience. Neurosurgery 2009;65:258

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Castaño C,
   2. Dorado L,
   3. Guerrero C,
   4. et al

   . Mechanical thrombectomy with the Solitaire AB device in large artery occlusions of the anterior circulation: a pilot study. Stroke 2010;41:1836–40

   Abstract/FREE Full Text
5. 5.↵
   1. Stampfl S,
   2. Hartmann M,
   3. Ringleb PA,
   4. et al

   . Stent placement for flow restoration in acute ischemic stroke: a single-center experience with the Solitaire stent system. AJNR Am J Neuroradiol 2011;32:1245–48

   Abstract/FREE Full Text
6. 6.↵
   1. Brekenfeld C,
   2. Schroth G,
   3. Mordasini P,
   4. et al

   . Impact of retrievable stents on acute ischemic stroke treatment. AJNR Am J Neuroradiol 2011;32:1269–73

   Abstract/FREE Full Text
7. 7.↵
   1. Nayak S,
   2. Ladurner G,
   3. Killer M

   . Treatment of acute middle cerebral artery occlusion with a Solitaire AB stent: preliminary experience. Br J Radiol 2010;83:1017–22

   Abstract/FREE Full Text
8. 8.↵
   1. Saver JL,
   2. Jahan R,
   3. Levy EI,
   4. et al.

   , for the SWIFT Trialists. Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012;380:1241–49

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Rovira A,
   2. Orellana P,
   3. Alvarez-Sabín J,
   4. et al

   . Hyperacute ischemic stroke: middle cerebral artery susceptibility sign at echo-planar gradient-echo MR imaging. Radiology 2004;232:466–73

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Flacke S,
    2. Urbach H,
    3. Keller E,
    4. et al

    . Middle cerebral artery (MCA) susceptibility sign at susceptibility-based perfusion MR imaging: clinical importance and comparison with hyperdense MCA sign at CT. Radiology 2000;215:476–82

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Liebeskind DS,
    2. Sanossian N,
    3. Yong WH,
    4. et al

    . CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke 2011;42:1237–43

    Abstract/FREE Full Text
12. 12.↵
    1. Cho KH,
    2. Kim JS,
    3. Kwon SU,
    4. et al

    . Significance of susceptibility vessel sign on T2*-weighted gradient echo imaging for identification of stroke subtypes. Stroke 2005;36:2379–83

    Abstract/FREE Full Text
13. 13.↵
    1. Barber PA,
    2. Hill MD,
    3. Eliaziw M,
    4. et al

    . Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry 2005;76:1528–33

    Abstract/FREE Full Text
14. 14.↵
    1. Smith WS,
    2. Sung G,
    3. Starkman S,
    4. et al

    . Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432–38

    Abstract/FREE Full Text
15. 15.↵
    1. Fiehler J,
    2. Knudsen K,
    3. Thomalla G,
    4. et al

    . Vascular occlusion sites determine differences in lesion growth from early apparent diffusion coefficient lesion to final infarct. AJNR Am J Neuroradiol 2005;26:1056–61

    Abstract/FREE Full Text
16. 16.↵
    1. Khatri P,
    2. Neff J,
    3. Broderick JP,
    4. et al

    . Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke 2005;36:2400–03

    Abstract/FREE Full Text
17. 17.↵
    1. Wong K,
    2. Lam WWM,
    3. Liang E,
    4. et al

    . Variability of magnetic resonance angiography and computed tomography angiography in grading middle cerebral artery stenosis. Stroke 1996;27:1084–87

    Abstract/FREE Full Text
18. 18.↵
    1. Wahlgren N,
    2. Ahmed N,
    3. Davalos A,
    4. et al

    . Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275–82

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Larrue V,
    2. von Kummer R,
    3. Müller A,
    4. et al

    . Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438–41

    Abstract/FREE Full Text
20. 20.↵
    1. Miteff F,
    2. Faulder K,
    3. Goh A,
    4. et al

    . Mechanical thrombectomy with a self-expanding retrievable intracranial stent (Solitaire AB): experience in 26 patients with acute cerebral artery occlusion. AJNR Am J Neuroradiol 2011;32:1078–81

    Abstract/FREE Full Text
21. 21.↵
    1. Costalat V,
    2. Machi P,
    3. Lobotesis K,
    4. et al

    . Rescue, combined, and stand-alone thrombectomy in the management of large vessel occlusion stroke using the Solitaire device: a prospective 50-patient single-center study. Stroke 2011;42:1929–35

    Abstract/FREE Full Text
22. 22.↵
    1. Ueda T,
    2. Sakaki S,
    3. Nochide I,
    4. et al

    . Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries. Stroke 1998;29:2568–74

    Abstract/FREE Full Text
23. 23.↵
    1. Suh DC,
    2. Kim JK,
    3. Choi JW,
    4. et al

    . Intracranial stenting of severe symptomatic intracranial stenosis: results of 100 consecutive patients. AJNR Am J Neuroradiol 2008;29:781–85

    Abstract/FREE Full Text
24. 24.↵
    1. Suh DC,
    2. Kim EH

    . The therapeutic time window related to the presenting symptom pattern, that is, stable versus unstable patients, can affect the adverse event rate of intracranial stenting. Stroke 2009;40:e588–89, author reply e590

    FREE Full Text
25. 25.↵
    1. Dorn F,
    2. Prothmann S,
    3. Wunderlich S,
    4. et al

    . Stent angioplasty of intracranial stenosis: single center experience of 54 cases. Clin Neuroradiol 2012;22:149–56

    CrossRefPubMed
26. 26.↵
    1. Abou-Chebl A,
    2. Steinmetz H

    . Critique of “Stenting versus aggressive medical therapy for intracranial arterial stenosis” by Chimowitz, et al in the New England Journal of Medicine. Stroke 2012;43:616–20

    Abstract/FREE Full Text
27. 27.↵
    1. Chimowitz MI,
    2. Lynn MJ,
    3. Derdeyn CP,
    4. et al

    . Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993–1003

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Ogata J,
    2. Masuda J,
    3. Yutani C,
    4. et al

    . Mechanisms of cerebral artery thrombosis: a histopathological analysis on eight necropsy cases. J Neurol Neurosurg Psychiatry 1994;57:17–21

    Abstract/FREE Full Text
29. 29.↵
    1. Komotar RJ,
    2. Mocco J,
    3. Wilson DA,
    4. et al

    . The natural history of intracranial carotid artery atherosclerosis. Neurosurg Focus 2005;18:e5

    PubMed
30. 30.↵
    1. Rauch U,
    2. Osende JI,
    3. Fuster V,
    4. et al

    . Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001;134:224

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Heo JH,
    2. Lee KY,
    3. Kim SH,
    4. et al

    . Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study. Neurology 2003;60:1684–87

    CrossRef
32. 32.↵
    1. Mangiafico S,
    2. Cellerini M,
    3. Nencini P,
    4. et al

    . Intravenous glycoprotein IIb/IIIa inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke. AJNR Am J Neuroradiol 2005;26:2595–601

    Abstract/FREE Full Text
33. 33.↵
    1. Torgano G,
    2. Zecca B,
    3. Monzani V,
    4. et al

    . Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. Cerebrovasc Dis 2010;29:275–81

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Kwon JH,
    2. Shin SH,
    3. Weon YC,
    4. et al

    . Intra-arterial adjuvant tirofiban after unsuccessful intra-arterial thrombolysis of acute ischemic stroke: preliminary experience in 16 patients. Neuroradiology 2011;53:779–85

    CrossRefPubMed
35. 35.↵
    1. Adams HP Jr.,
    2. Effron MB,
    3. Torner J,
    4. et al

    . Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008;39:87–99

    Abstract/FREE Full Text
36. 36.↵
    1. Johnston DC,
    2. Hill MD

    . The patient with transient cerebral ischemia: a golden opportunity for stroke prevention. CMAJ 2004;170:1134–37

    Abstract/FREE Full Text
37. 37.↵
    1. Jakubowska MM,
    2. Michels P,
    3. Müller-Jensen A,
    4. et al

    . Endovascular treatment in proximal and intracranial carotid occlusion 9 hours after symptom onset. Neuroradiology 2008;50:599–604

    CrossRefPubMed